We are international
Donate
• health professionals TEXT SIZE   
Bringing the Experts to You

ASH 2006 - Webcasts

ASH Overview
12.23.07   Overview of ASH 2006 in Czech
Prof. Roman Hájek
Masaryk University
Brno, Czech Republic

12.17.07   Ein Überblick über den ASH-Kongress
Hartmut Goldschmidt, MD
Universitätsklinikum Heidelberg (University Clinic of Heidelberg) und Nationales Centrum für Tumorerkrankungen (and the National Center of Tumor Diseases)
Heidelberg, Deutschland

Novel Agents - Newly-Diagnosed Myeloma
12.17.06   A Randomized Study of Lenalidomide with High- or Low-Dose Dexamethasone in the Treatment of Newly Diagnosed Myeloma
S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, MN

12.17.06   An International Randomized Trial of Thal/Dex vs Dexamethasone Alone
S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, MN

12.17.06   An Overview of Planned Randomized Clinical Trials for Newly Diagnosed Younger and Older Patients in Spain
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain

12.17.06   Analysis of Phase III Study of Revlimid + Dexamethasone in Patients >65 Years
Asher A. Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, NY

12.17.06   Breaking the Plateau Response in MM: Results of a Pilot Study of Vel/Dex/Doxil (DoVeD)
Ruben Niesvizky, MD
New Presbyterian Hospital
Weill Cornell Medical Center
New York, NY

12.17.06   Identification of Mutations in the NFkB Pathway That Predict Velcade Response
A. Keith Stewart, MD
Mayo Clinic
Scottsdale, AZ

12.17.06   Long Term Results of a Study of Rev/Dex in Newly Diagnosed Patients
Martha Q. Lacy, MD
Mayo Clinic
Rochester, MN

12.17.06   Long-Term Follow-Up of a Phase II Trial of Vel/Dex in Frontline Therapy for Myeloma
Sundar Jagannath, MD
St. Vincent’s Comprehensive Cancer Center
New York, NY

12.17.06   Phase I/II Study of Revlimid + Melphalan/Prednisone (R-MP) for Newly Diagnosed Myeloma
Antonio Palumbo, MD
Ospedale Molinette
Torino, Italy

12.17.06   Relationship Between Quality of Response to Velcade and Clinical Benefit
Ruben Niesvizky, MD
New Presbyterian Hospital
Weill Cornell Medical Center
New York, NY

12.17.06   Revlimid-Induced Myelosuppression is Potentially Associated with Renal Dysfunction in Treatment-Naïve MM Patients Receiving BiRD
Ruben Niesvizky, MD
New Presbyterian Hospital
Weill Cornell Medical Center
New York, NY

12.17.06   The Use of Lenalidomide +/- Dexamethasone in Patients with AL Amyloidosis
Angela Dispenzieri, MD
Mayo Clinic
Rochester, MN

12.17.06   The Use of Velcade + Melphalan/Prednisone in Elderly Non-Transplant Patients
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain

12.17.06   The Use of Velcade as First-Line Therapy in High-Risk Myeloma
Angela Dispenzieri, MD
Mayo Clinic
Rochester, MN

12.17.06   Use of Revlimid With or Without Steroids in Relapsed/Refractory Myeloma Patients with Elevated Baseline Serum Creatinine
Donna E. Reece, MD
Princess Margaret Hospital
Toronto, Canada

12.17.06   Velcade and Doxil as Induction Therapy for Newly Diagnosed Myeloma
Robert Z. Orlowski, MD
Lineberger Cancer Center
University of North Carolina
Chapel Hill, NC

Novel Agents - Relapsed/Refractory Myeloma
12.17.06   A Phase I/II Study of Revlimid, Adriamycin, and Dexamethasone (RAD) in Patients with Relapsed/Refractory Myeloma
Stefan Knop, MD
Universitätsklinikums Würzburg (University Clinic of Wuerzburg)
Würzburg, Germany

12.17.06   A Phase II Study of Velcade, Doxil, and Thalidomide (VDT) in Relapsed/Refractory Myeloma
Asher A. Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, NY

12.17.06   A Subset Study of Lenalidomide/Dexamethasone vd Dexamethasone Alone After Thalidomide Therapy in Relapsed/Refractory Myeloma
Michael Wang, MD
MD Anderson Cancer Center
Houston, Texas USA

12.17.06   Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma
Heinz Ludwig, MD
Wilhelminenspital der Stadt Wein
Vienna, Austria

12.17.06   Combination of Revlimid and Velcade in the Treatment of Relapsed/Refractory Myeloma
Paul G. Richardson, MD
Dana Farber Cancer Institute
Boston, Massachusetts USA

12.17.06   Phase I Study of BB-10901 (huN901-DM1) in Patients with Relapsed/Refractory CD56-Positive Myeloma
Asher A. Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, NY

12.17.06   Phase I/II Study of a Combination of Velcade, Melphalan, Prednisone, and Thalidomide (VMPT) for Relapsed Myeloma
Antonio Palumbo, MD
Ospedale Molinette
Torino, Italy

12.17.06   Phase I/II Study of Oral Cyclophosphamide, Prednisone, and Velcade in Patients with Relapsed/Refractory Myeloma
Donna E. Reece, MD
Princess Margaret Hospital
Toronto, Canada

12.17.06   Phase III International Randomized Study of Velcade vs Velcade/Doxil in Relapsed/Refractory Myeloma
Robert Z. Orlowski, MD
Lineberger Cancer Center
University of North Carolina
Chapel Hill, NC

12.17.06   Revlimid in Combination with Dex is More Effective than Dexamethasone Alone at First Relapse
Edward A. Stadtmauer, MD
Hospital of the University of Pennsylvania
Philadelphia, PA

New Agents and Approaches
12.17.06   A Phase I Study of HCD122 (formerly CHIR1212), a Monoclonal Antibody to CD40, in Relapsed/Refractory Myeloma
William Bensinger, MD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, WA

12.17.06   A Retrospective Study of the Significance of Complete Response (CR) on Outcomes in Myeloma Treatment
Michael Wang, MD
MD Anderson Cancer Center
Houston, Texas USA

12.17.06   Mi-63, a Small Molecule Inhibitor of MDM2-p53 Interaction, Has Significant In Vitro Activity in Multiple Myeloma
Shaji Kumar, MD
Mayo Clinic
Rochester, MN

12.17.06   New Proteasome Inhibitor NPI-0052
Michael Palladino, PhD
Nereus Pharmaceuticals
San Diego, CA

12.17.06   Phase I Study of KOS-953 + Velcade in Patients with Relapsed/Refractory MM
Paul G. Richardson, MD
Dana Farber Cancer Institute
Boston, Massachusetts USA

12.17.06   SNP Association with Event-Free Survival (EFS) in Myeloma from Two Phase III Trials Using the Bank On A Cure SNP Chip
Brian Van Ness, PhD
University of Minnesota
Institute of Human Genetics
Minneapolis, MN

12.17.06   The Effect of Genetically Modified Measles Virus on Myeloma Cells in Vitro
Hermann Einsele, MD
Universitätsklinikums Würzburg (University Clinic of Wuerzburg)
Würzburg, Germany

12.17.06   The Genetic Contribution to the Etiology of Thalidomide-Associated VTE
Gareth Morgan, MD
The Royal Marsden Hospital
Sutton, Surrey, UK

Transplantation
12.17.06   A Phase I/II Study of Consolidation Therapy with Velcade after Tandem Transplant
Hermann Einsele, MD
Universitätsklinikums Würzburg (University Clinic of Wuerzburg)
Würzburg, Germany

12.17.06   A Phase II Study of Alternating Velcade and Dexamethasone as Induction Therapy Prior to Transplant in Newly Diagnosed Patients
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain

12.17.06   A Retrospective Analysis of High Dose Therapy in Patients with Renal Insufficiency
Shaji Kumar, MD
Mayo Clinic
Rochester, MN

12.17.06   A Retrospective Analysis of the Significance of Measurable Disease at Time of Transplant
Shaji Kumar, MD
Mayo Clinic
Rochester, MN

12.17.06   A Retrospective Analysis of Three Induction Regimens for Newly Diagnosed Myeloma Prior to Transplant
Shaji Kumar, MD
Mayo Clinic
Rochester, MN

12.17.06   A Retrospective Study of the Significance of VGPR/CR in the IFM 99 Trials
Jean-Luc Harousseau, MD
Hematologie Clinique
CHU Hotel Dieu
Nantes, France

12.17.06   An Analysis of Response Criteria Post-Stem Cell Transplant in AL Amyloidosis
Morie Gertz, MD
Mayo Clinic
Rochester, MN

12.17.06   An Interim Analysis of Velcade/Dexamethasone vs VAD as Induction Therapy Prior to Transplant in Newly Diagnosed Myeloma
Jean-Luc Harousseau, MD
Hematologie Clinique
CHU Hotel Dieu
Nantes, France

12.17.06   Prospective Randomized Comparison of Double Transplant with Melphalan 200 vs Triple Transplant with Melphalan 100
Heinz Ludwig, MD
Wilhelminenspital der Stadt Wein
Vienna, Austria

12.17.06   Velcade Added to High-Dose Cytoxan and GCSF as a Mobilization Regimen for Stem Cell Collection Prior to HDT
Ruben Niesvizky, MD
New Presbyterian Hospital
Weill Cornell Medical Center
New York, NY